Drugs that contain Cladribine

1. List of Mavenclad drug patents

MAVENCLAD's oppositions filed in EPO
MAVENCLAD Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7888328 EMD SERONO INC Oral formulations of cladribine
Apr, 2024

(1 year, 9 days from now)

US8785415 EMD SERONO INC Oral formulations of cladribine
Apr, 2024

(1 year, 9 days from now)

US8377903 EMD SERONO INC Cladribine regimen for treating multiple sclerosis
May, 2026

(3 years from now)

US7713947 EMD SERONO INC Cladribine regimen for treating multiple sclerosis
Oct, 2026

(3 years from now)

US10849919 EMD SERONO INC Cladribine regimen for treating progressive forms of multiple sclerosis
Nov, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Mar 29, 2022

Market Authorisation Date: 29 March, 2019

Treatment: Treatment of ms with a tablet with an admixture of (a) an amorphous inclusion complex of cladribine and hydroxypropyl-b-cyclodextrin and (b) amorphous free cladribine and cyclodextrin as a non-inclusi...

Dosage: TABLET;ORAL

How can I launch a generic of MAVENCLAD before it's patent expiration?
More Information on Dosage

MAVENCLAD family patents

17

United States

13

European Union

10

Japan

8

Australia

8

Spain

5

Denmark

5

Brazil

5

China

5

Canada

4

Mexico

4

Lithuania

4

Slovenia

4

Hungary

4

Portugal

4

Korea, Republic of

4

Poland

EA

4

EA

3

South Africa

3

Norway

3

Argentina

3

Singapore

3

Croatia

3

Cyprus

3

Ukraine

3

ME

2

Israel

2

Austria

2

Hong Kong

YU

2

Yugoslavia

2

Iceland

2

Luxembourg

1

Russia

1

Germany

1

Taiwan, Province of China

1

RS

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in